Meeting
2013 Gastrointestinal Cancers Symposium
A phase ll study of trastuzumab in combination with triweekly S-1 plus CDDP in HER2-positive advanced gastric cancer (HERBIS-1).
Authors
Naotoshi Sugimoto
Department of Clinical Oncology and Gastrointestin
Naotoshi Sugimoto , Junji Tanaka , Masahiro Tsuda , Wataru Okamoto , Hiroyuki Okuda , Hiroshi Imamura , Toshio Shimokawa , Daisuke Sakai , Yukinori Kurokawa , Yoshito Komatsu , Chikashi Ishioka , Toshimasa Tsujinaka , Hiroya Takiuchi , Hiroshi Furukawa
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
General Poster Session A: Cancers of the Esophagus and Stomach
Track
Cancers of the Esophagus and Stomach
Sub Track
Multidisciplinary Treatment
Clinical Trial Registration Number
UMIN000005739
Citation
J Clin Oncol 31, 2013 (suppl 4; abstr70)
DOI
10.1200/jco.2013.31.4_suppl.70
Abstract #
70
Poster Bd #
B14
Abstract Disclosures
Similar Posters
Poster
2017 ASCO Annual Meeting
A phase II study (KSCC/HGCSG/CCOG/PerSeUS1501B) of trastuzumab plus S-1 and oxaliplatin for HER2-positive advanced gastric cancer.
First Author: Katsunori Shinozaki
Poster
2014 Gastrointestinal Cancers Symposium
Trastuzumab (T-mab) in combination with docetaxel/cisplatin/S-1 (DCS) for patients with HER2-positive metastatic gastric cancer: Feasibility and preliminary efficacy.
First Author: Yasushi Sato
Poster
2014 Gastrointestinal Cancers Symposium
Phase II study of trastuzumab in combination with capecitabine and oxaliplatin in patients with advanced gastric cancer.
First Author: Min-Hee Ryu
Poster
2013 ASCO Annual Meeting
A phase ll study of new combination regimen with trastuzumab, S-1, and CDDP in HER2-positive advanced gastric cancer (HERBIS-1).
First Author: Keisuke Koeda